Payment overview · 2025
General Payments
$2,099.24
122 reported records · 26 companies
Healthcare provider profile · identity verified
Christopher Dickson Hayes, MD
Allopathic & Osteopathic Physicians|Family Medicine · EDMOND, OK · NPI 1770669863
Verified facts
What the public records show
CMS Open Payments records show Christopher Dickson Hayes, MD received $2,099.24 in general payments during 2025 across 122 reported records.
PFIZER INC. accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Mounjaro, Otezla, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $315.94 | 15.1% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $304.39 | 14.5% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $210.92 | 10.1% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $174.94 | 8.3% | 12 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $158.11 | 7.5% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $139.84 | 6.7% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $136.08 | 6.5% | 9 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $101.02 | 4.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $65.08 | 3.1% | 4 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $48.00 | 2.3% | 3 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $44.00 | 2.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $41.02 | 1.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.88 | 1.9% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $36.73 | 1.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.90 | 1.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.42 | 1.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.60 | 1.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.85 | 1.2% | 3 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $25.71 | 1.2% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $24.66 | 1.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.16 | 1.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $21.43 | 1.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.97 | 1.0% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $18.56 | 0.9% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $16.40 | 0.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.63 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,099.24 | 122 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $182.36 | 8 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $169.69 | 9 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $158.11 | 8 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $151.41 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $150.78 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $146.25 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $145.17 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $136.08 | 9 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $130.48 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $120.33 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $107.53 | 7 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $101.02 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $90.06 | 5 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $90.06 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $83.45 | 7 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $65.08 | 4 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $57.49 | 3 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $57.49 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $56.39 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $53.39 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.63 | 3 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $48.00 | 3 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $48.00 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45.26 | 3 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $44.00 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $41.02 | 2 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $36.73 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.90 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.42 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.42 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $27.60 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.92 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.85 | 3 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $25.71 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $25.71 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $25.71 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $25.71 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.97 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 172 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 252 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 21 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
53 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
101 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
101 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
252 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
172 | 44 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 803 | 227 |
| Levothyroxine Sodium | Levothyroxine Sodium | 732 | 191 |
| Amlodipine Besylate | Amlodipine Besylate | 518 | 154 |
| Lisinopril | Lisinopril | 412 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 412 | 121 |
| Losartan Potassium | Losartan Potassium | 345 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 323 | 100 |
| Omeprazole | Omeprazole | 319 | 85 |
| Gabapentin | Gabapentin | 306 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 263 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 259 | 75 |
| Mounjaro | Tirzepatide | 252 | 49 |
| Trazodone Hcl | Trazodone Hcl | 248 | 73 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 246 | 75 |
| Celecoxib | Celecoxib | 230 | 82 |
| Simvastatin | Simvastatin | 195 | 52 |
| Eliquis | Apixaban | 172 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 169 | 50 |
| Meloxicam | Meloxicam | 167 | 61 |
| Montelukast Sodium | Montelukast Sodium | 162 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 156 | 44 |
| Metformin Hcl | Metformin Hcl | 142 | 46 |
| Furosemide | Furosemide | 130 | 50 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 129 | 38 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 127 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 126 | 34 |
| Bupropion Xl | Bupropion Hcl | 123 | 37 |
| Glipizide Er | Glipizide | 121 | 38 |
| Allopurinol | Allopurinol | 119 | 35 |
| Finasteride | Finasteride | 116 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 116 | 53 |
| Carvedilol | Carvedilol | 113 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 111 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 34 |
| Potassium Chloride | Potassium Chloride | 108 | 34 |
| Sertraline Hcl | Sertraline Hcl | 108 | 34 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 103 | 30 |
| Jardiance | Empagliflozin | 101 | 28 |
| Ozempic | Semaglutide | 101 | 28 |
| Colestipol Hcl | Colestipol Hcl | 99 | 32 |
| Donepezil Hcl | Donepezil Hcl | 93 | 25 |
| Tramadol Hcl | Tramadol Hcl | 92 | 42 |
| Estradiol | Estradiol | 91 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 22 |
| Metformin Hcl Er | Metformin Hcl | 85 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 22 |
| Pregabalin | Pregabalin | 83 | 26 |
| Doxazosin Mesylate | Doxazosin Mesylate | 82 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 38 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 75 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 72 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 21 |
| Buspirone Hcl | Buspirone Hcl | 67 | 21 |
| Xarelto | Rivaroxaban | 66 | 15 |
| Ezetimibe | Ezetimibe | 62 | 19 |
| Atenolol | Atenolol | 61 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | 17 |
| Alprazolam | Alprazolam | 59 | 18 |
| Famotidine | Famotidine | 59 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 16 |
| Synthroid | Levothyroxine Sodium | 58 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 18 |
| Farxiga | Dapagliflozin Propanediol | 54 | 15 |
| Myrbetriq | Mirabegron | 53 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 19 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 51 | 13 |
| Repatha Sureclick | Evolocumab | 51 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | 14 |
| Methylprednisolone | Methylprednisolone | 45 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 20 |
| Lovastatin | Lovastatin | 44 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 43 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 39 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | 11 |
| Valsartan | Valsartan | 39 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 13 |
| Naproxen | Naproxen | 38 | 16 |
| Nifedipine Er | Nifedipine | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | 12 |
| Primidone | Primidone | 37 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Acyclovir | Acyclovir | 34 | 13 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Azithromycin | Azithromycin | 31 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | 12 |
| Prednisone | Prednisone | 31 | 27 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 17 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Diazepam | Diazepam | 23 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | 13 |
| Gemtesa | Vibegron | 22 | suppressed |
| Nabumetone | Nabumetone | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 12 |
| Testosterone | Testosterone | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 16 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Glyxambi | Empagliflozin/Linagliptin | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Esbriet | Pirfenidone | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Butrans | Buprenorphine | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,099.24 · 122 records | PFIZER INC. | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, BEYFORTUS, CHARTIS CATHETER, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, GEMTESA, Heplisav-B, JASCAYD, KISUNLA, Kerendia, LINZESS, Leqembi, MENQUADFI, MONOFERRIC, MOUNJARO, NEXPLANON, NP Thyroid 60, NURTEC ODT, OFEV, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, PULMONX CHARTIS TABLET CONSOLE, QULIPTA, REPATHA, Rybelsus, SHINGRIX, Symbravo, TRUMENBA, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error